City

Groton

2-90-6

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

ease type a plus sign (+) inside this box ->

Attorney Docket No. PC10934AGPR

First Named Inventor or Application Identifier Richard John Bazin

Title Crystal Structure

Express Mail Label No. EL911725549US (Only for new nonprovisional applications under 37C.F.R. §1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 1. *Fee Transmittal Form (e.g., PTO/SB/17) 6. Microfiche Computer Program (Appendix) (Submit an original, and a duplicate for fee processing) 7. Nucleotide and/or Amino Acid Sequence Submission 2. Specification [Total Pages 462 (if applicable, all necessary) (preferred arrangement set forth below) Descriptive title of the Invention Computer Readable Copy Cross References to Related Applications b. Paper Copy (identical to computer copy) Statement Regarding Fed sponsored R&D Reference in Microfiche Appendix c Statement verifying identity of above copies Background of the Invention ACCOMPANYING APPLICATION PARTS Brief Summary of the Invention 8. Assignment Papers (cover sheet & document(s)) Brief Description of the Drawings (if filed) **Detailed Description** 9. 37 C.F.R §3.73(b) Statement Power of Attorney Claim(s) (when there is an assignee) Abstract of the Disclosure 10. English Translation Document (if applicable) Information Disclosure 11. Copies of IDS Drawing(s) (35 U.S.C. 11.3)[Total sheets Statement (IDS)/PTO-1449 Citations Oath or Declaration [Total pages 12. Preliminary Amendment Newly executed (original or copy) 13 Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Copy from a prior application (37 CFR §1.63(d)) Statement filed in prior application, 14. *Small Entity (for continuation/divisional with Box 17 completed) Status still proper and desired Statement(s) [Note Box 5 below] (PTO/SB/09-12) DELETION OF INVENTOR(S) Certified Copy of Priority Document(s) 15. Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Incorporation By Reference (useable if Box 4b is checked) Other: Priority Claim The entire disclosure of the prior application, from which a U.K. Provisional Application No. 0030424.6, copy of the oath or declaration is supplied under Box 4b, is filed December 13, 2000 and U.S. Provisional considered to be part of the disclosure of the accompanying Application No. 60/260,627, filed January 10, application and is hereby incorporated by reference therein. 2001. *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment. Continuation Divisional Continuation-in-part (CIP) of prior application No: Prior application information: Examiner Group/Art Unit: 18. CORRESPONDENCE ADDRESS (Insert Customer No. or Attach bar code label here) Customer Number or Bar Code Label Correspondence address below Name Gregg C. Benson Address Pfizer Inc. Address Patent Department, MS 4159, Eastern Point Road

 Country
 United States Of America
 Telephone
 1-(860)-441-4901
 Fax
 1-(860)-441-5221

 NAME (Print/type)
 Gregory P. Raymer
 Registration No. (Attorney/Agent)
 36,647

 Signature
 Date
 12/13/01

CT

Zip Code

06340

State

					00, 11 (200
		App	roved for us	se through	09/30/2000
MB 0651-0032	Patent and Tradema	rk Office: U.S.	DEPARTM	ENT OF C	OMMERCI

				To be assigned			
FEE TRANSMITTAL	Application Number		To be assigned				
0 42		Filing Date			Concurrently Herewith		
Patent fees are subject to annual revision on October 1. These are the fees effective October 1,. 2001.		First Named Inventor			Richard John Bazin		
Fuil Entity payments <u>must</u> be supported by a small entity statement, merwise large entity fees must be paid. See Forms PTO/SB/09-12.		Examiner Name			To be assigned		
See 37 C.F.R. §§ 1.27 and 1.28.		Group/Art Unit		To be assigned			
Total Amount of Payment (\$)1,038.00		Attorney Docket No.		PC10934AGPR			
METHOD OF PAYMENT (check one)	<u> </u>			FEE CA	LCULATION (continued	1)	
1. The commissioner is hereby authorized to charge		IONAL F	EES		(00,111,000		
indicated fees and credit any over payments to:		Large Entity Small Entity					
Deposit Account 16-1445		Fee	Fee	Fee	F B		
Number	Code	(\$)	Code	(\$)	Fee Description	on	Fee Paid
Deposit Account Name Pfizer Inc.	105	130	205	65	Surcharge - late fee or	oath	
☐ Charge Any Additional ☐ Charge the Issue Fee Set in		50	227	25	Surcharge-late provision cover sheet	onal filing fee or	
37 Fee Required Under 37 C.F.R. § 1.1.8 at the Mailing C.F.R. §§ 1.1.6 and 1.17. of the Notice of Allowance	139	130	139	130	Non-English specification	on	
	147	2,520	147	2,520	For filing a request for r	reexamination	
2. Payment Enclosed:		920*	112	920*	Requesting publication		
☐ Check ☐ Money Order ☐ Other		1,840*	113	1,840*	Examiner action Requesting publication		
FEE CALCULATION	115	110	215	55	Examiner action	t- 6	
1 BASIC FILING FEE	116	400	215	55	Extension for reply with		
	110	400	216	200	Extension for reply with month	in second	
Large Entity Small Entity	117	920	217	460	Extension for reply within	in third month	
Eee Fee Fee Fee Description Fee Paid Cede (\$) Code (\$)	118	1,440	218	720	Extension for reply with	in fourth month	
740 00 Utility filing fee 740 00	128	1,960	228	980	Extension for reply within	in fifth month	
a)06 330 206 165 Design filing fee	119	320	219	160	Notice of Appeal		
107 510 207 255 Plant filling fee	120	320	220	160	Filing a brief in support	of an appeal	
108 740 208 370 Reissue filing fee	121	280	221	140	Request for oral hearing	9	
160 214 80 Provisional filing fee	138	1,510	138	1,510	Petition to institute a pul proceeding	blic use	
SUBTOTAL (1) (\$) 740 00		110	240	55	Petition to revive - unave	oidable	
2. EXTRA CLAIM FEES		1,280	241	640	Petition to revive - uninte	entional	
Extra Fee from Claims below Fee Paid	142	1,280	242	640	Utility issue fee (or reiss	sue)	
Total Claims 25 -20**= 5 X 18 00 = 90 00	143	460	243	230	Design issue fee		
Independent 5 - 3**= 2 X 84.00 = 168.00	144	620	244	310	Plant issue fee		
Multiple Dependent = 0	122	130	122	130	Petitions to the Commiss	sioner	
** or number previously paid, if greater; For Reissues, see below Large Entity Small Entity		50	123		Petitions related to provi applications	isional	
Fee Fee Fee Fee Description Code (\$) Code (\$)	126	180	126	180	Submission of Information	on Disclosure	
103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent a		40 00
102 84 202 42 Independent claims in excess of 3	146	740	246		property (times number of Filing a submission after		
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	(37 CFR 1.129(a)) For each additional inve	ntion to be	
109 84 209 42 **Reissue independent claims over		(specify)			examined (37 CFR 1 129	9(b))	
original patent 110 18 210 9 **Reissue claims in excess of 20 and		Other Fee (specify)		•			
over original patent SUBTOTAL (2) (\$) 258.00	*Reduced I	by Basic	Filing Fe	e Paid	SUBTOTAL (3) (\$)	40.00
SUBMITTED BY	-	,			Complete (if Applicable)		
Type or Printed Name Gregory P Raymer				Reg Number 36,647			
Signature	Date	12	/13/0	71	Deposit Account	16-1445	
- Layma		12	110/0	<u>′1 </u>	User ID		

Patent Application

Attorney Docket No. PCS10934AGPR

graf Speri
M
M
Į.
M
4
ğal.
M
ļū
j ah

By Deanna L. Miler	
(Signature of person mailing)	
Deanna L. Miller	
(Typed or printed name of person)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Richard John Bazin, et al :

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: Crystal Structure :

Box SEQUENCE Director – U.S. Patent and Trademark Office Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Date: 12/13/01

Gregory P. Raymer

Attorney for Applicant(s)

Reg. No. 36,647

Pfizer Inc.

Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-5746